Articles dans des revues avec comité de lecture (396)
  1. 61. Başaran, G. A., Twelves, C., Diéras, V., Cortes, J., & Awada, A. (2018). Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer treatment reviews, 63, 144-155. doi:10.1016/j.ctrv.2017.12.002
  2. 62. Kotecki, N., Lefranc, F., Devriendt, D., & Awada, A. (2018). Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives. Therapeutic advances in medical oncology, 10. doi:10.1177/1758835918780312
  3. 63. Vasconcellos, V. F., Colli, L. M., Awada, A., & de Castro Junior, G. (2018). Precision oncology: as much expectations as limitations. ecancermedicalscience, 12, ed86. doi:10.3332/ecancer.2018.ed86
  4. 64. Closset, C., Ameye, L., Gebhart, M., De Saint Aubain, N., Beauvois, S., Awada, A., Piccart-Gebhart, M., & Gil, T. (2018). Long-Term Clinical Outcome and Survivorship Issues of High Grade Bone Sarcomas. International journal of cancer and oncology, 5(1), 26-34. doi:10.15436/2377-0902.18.1522
  5. 65. Traina, T. T., Miller, K., Yardley, D., Eakle, J., Schwartzberg, L. L., O'Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., Nanda, R., Gucalp, A., Awada, A., Garcia-Estevez, L., Trudeau, M. E., Steinberg, J., Uppal, H., Tudor, I. C., Peterson, A., & Cortes, J. (2018). Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. Journal of clinical oncology, 36(9), 884-890. doi:10.1200/JCO.2016.71.3495
  6. 66. Perdrix, A., Najem, A., Saussez, S., Awada, A., Journé, F., Ghanem, G. E., & Krayem, M. (2017). PRIMA-1 and PRIMA-1Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers (Basel), 9(12), 172. doi:10.3390/cancers9120172
  7. 67. Awada, G., de Azambuja, E., & Awada, A. (2017). Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. Expert Opinion on Drug Metabolism & Toxicology, 13(12), 1205-1215. doi:10.1080/17425255.2017.1398733
  8. 68. Aftimos, P., Van Rompaey, L., Michotte, J.-M., Silence, K., Hultberg, A., Gandini, D., De Haard, H., Ribrag, V., Peeters, M., Thibault, A., Leupin, N., Rolfo, C., Awada, A., Rottey, S., Offner, F., Bron, D., Maerevoet, M., Soria, J.-C., Moshir, M., & Dreier, T. (2017). Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies. Clinical cancer research, 23(21), 6411-6420. doi:10.1158/1078-0432.CCR-17-0613
  9. 69. Najem, A., Krayem, M., Perdrix, A., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2017). New drug combination strategies in melanoma: Current status and future directions. Anticancer research, 37(11), 5941-5953. doi:10.21873/anticanres.12041
  10. 70. Lonez, C., Verma, B., Hendlisz, A., Aftimos, P., Awada, A., Van Den Neste, E., Catala, G., Machiels, J. P. J., Piette, F., Brayer, J. J., Sallman, D. D., Kerre, T., Odunsi, K., Davila, M. M., Gilham, D., & Lehmann, F. (2017). Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ open, 7(11), e017075. doi:10.1136/bmjopen-2017-017075
  11. 71. Najem, A., Krayem, M., Sales, F., Hussein, N., Badran, B., Robert, C., Awada, A., Journé, F., & Ghanem, G. E. (2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European journal of cancer, 83, 154-165. doi:10.1016/j.ejca.2017.06.033
  12. 72. Kotecki, N., Penel, N., & Awada, A. (2017). How to emerge from the conservatism in clinical research methodology? Current opinion in oncology, 29(5), 400-404. doi:10.1097/CCO.0000000000000399
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>